

Simons Foundation Autism Research Initiative: Resources

<https://sfari.org>

Arbaclofen

- Clinical Research Associates, a wholly-owned nonprofit subsidiary of the Simons Foundation, acquired all rights to arbaclofen from Seaside Therapeutics
- We are planning further clinical development
- We make arbaclofen available for investigator-initiated studies in animals and humans

Grants programs

- Annual RFA and Explorer Awards
 - Extensive basic neuroscience/genetics portfolio
 - Opportunity for funding of clinical research applications (e.g., biomarkers, endpoint development, experimental medicine, translational studies)
- Targeted Awards
 - 2015 Novel Outcome Measures RFA
 - Four applications funded: eye tracking, biomarkers of social function and emotional regulation, expressive language outcome measures

Simons Cohorts

- Simons Simplex Collection
 - 2600 simplex families including unaffected parents and sibs
 - Rigorous phenotyping including MRI, MRS, MEG
 - SNP and whole exome genotyping (whole genome in progress)
 - All de-identified data available
 - Biospecimens available
 - 1500 families available for re-contacting for future studies

Simons Cohorts 2

- Variations in Individuals Project (VIP)
 - Phase I:
 - 16p11.2 deletions and duplications (N=200)
 - 1q21.1 deletions and duplications (N =25)
 - Very deep phenotyping and neuroimaging
 - Data and biospecimens available
 - Phase II:
 - 37 single gene mutations associated with ASD; online and telephone phenotyping; followed longitudinally

Simons Cohorts 3

- SPARK (National Autism Cohort; sparkforautism.org)
 - 50,000 individuals with ASD plus parents and unaffected sib
 - All will be genotyped
 - Detailed medical/history information, online assessments
 - Provision to search de-identified data and identify subjects for clinical trials
 - Re-contact for clinical trial participation

<https://sfari.org>